What question did this study set out to answer?

To investigate the role of RBM17 in MDS patient outcomes and its mechanism in cell proliferation.

December 8, 2025BloodOpen Access

The variable splicing factor RBM17 regulates MDS cell proliferation through H3K27la

View Full Paper

Ask AI

Bookmark

Authors

Overexpression of RBM17 inhibits cell proliferation in MDS, suggesting potential therapeutic targets in hemat malignancies.

To investigate the role of RBM17 in MDS patient outcomes and its mechanism in cell proliferation.
Collected bone marrow cells from healthy volunteers and MDS patients for single-cell sequencing.
Conducted Kaplan-Meier analysis based on RBM17 expression levels in MDS patients.
Performed RNA-seq and GSEA analysis on MDS cell lines overexpressing RBM17.
RBM17 expression is down-regulated in MDS patients, correlating with poor prognosis.
Overexpression of RBM17 inhibits MDS cell proliferation and reduces lactic acid production.
RBM17 regulates H3K27la through glycolysis in MDS cells.

Wang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark